ARMP 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等,已經有部位可以持續持有,若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

ARMP 近期報酬表現

11.94%

Armata pharmaceuticals inc

7.48%

同產業平均

-0.88%

S&P500

與 ARMP 同產業的標的表現

  • UPC Universe pharmaceuticals inc
    價值 1 分趨勢 5 分波段 3 分籌碼 -股利 1 分
    查看更多

ARMP 公司資訊

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

ARMP 股價